CTIM-27. PHASE I/II STUDY OF CONTROLLED IL-12 AS IMMUNOTHERAPY FOR DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)

DIPG, which is the leading cause of pediatric brain cancer death with no effective treatment, has neither a highly immunosuppressive nor inflammatory tumor microenvironment (TME). Therefore, eliciting a pro-inflammatory TME may provide therapeutic benefit. We previously demonstrated in adults with r...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Neuro Oncol
Hlavní autoři: Goldman, Stewart, Mueller, Sabine, Chi, Susan, Saratsis, Amanda, Allen, Rudy, Buck, Jill, Demars, Nathan, Hadar, Nira, Estupinan, Taylor, Miao, John, Walsh, Erin, Gelb, Arnold, Cooper, Laurence
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2020
Témata:
Clinical Trials: Immunologic
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650466/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.161
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky